HSCS official logo HSCS
HSCS 1-star rating from Upturn Advisory
Heart Test Laboratories Inc. Common Stock (HSCS) company logo

Heart Test Laboratories Inc. Common Stock (HSCS)

Heart Test Laboratories Inc. Common Stock (HSCS) 1-star rating from Upturn Advisory
$2.55
Last Close (24-hour delay)
upturn advisory logo
PASS
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock price based on last close icon Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • 1Y
  • 1M
  • 1W

Upturn Advisory Summary

12/12/2025: HSCS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Upturn 1 star rating for performance

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

1 star rating from financial analysts

2 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $10.5

1 Year Target Price $10.5

Analysts Price Target For last 52 week
$10.5 Target price
52w Low $2.01
Current$2.55
52w High $6.47

Analysis of Past Performance

Type Stock
Historic Profit -66.41%
Avg. Invested days 15
Today’s Advisory PASS
Upturn Star Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 12/12/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.49M USD
Price to earnings Ratio -
1Y Target Price 10.5
Price to earnings Ratio -
1Y Target Price 10.5
Volume (30-day avg) 2
Beta 2.58
52 Weeks Range 2.01 - 6.47
Updated Date 11/14/2025
52 Weeks Range 2.01 - 6.47
Updated Date 11/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -8.28

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -98637.84%

Management Effectiveness

Return on Assets (TTM) -69.65%
Return on Equity (TTM) -193.24%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 7165336
Price to Sales(TTM) 1281.58
Enterprise Value 7165336
Price to Sales(TTM) 1281.58
Enterprise Value to Revenue 1146.45
Enterprise Value to EBITDA -0.14
Shares Outstanding 3071135
Shares Floating 2573920
Shares Outstanding 3071135
Shares Floating 2573920
Percent Insiders 3.02
Percent Institutions 3.59

About Heart Test Laboratories Inc. Common Stock

Exchange NASDAQ
Headquaters Southlake, TX, United States
IPO Launch date 2022-06-15
CEO, President & Chairman of the Board of Directors Mr. Andrew Simpson
Sector Healthcare
Industry Medical Devices
Full time employees 15
Full time employees 15

HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.